Application of lipid nanovesicle drug delivery system in cancer immunotherapy

被引：50

作者：

Ding, Yinan ^{[1
]}

Wang, Luhong ^{[1
]}

Li, Han ^{[2
]}

Miao, Fengqin ^{[1
]}

Zhang, Zhiyuan ^{[3
]}

Hu, Chunmei ^{[2
]}

Yu, Weiping ^{[1
]}

Tang, Qiusha ^{[1
]}

Shao, Guoliang ^{[4
]}

机构：

[1] Southeast Univ, Med Sch, Nanjing 210009, Peoples R China

[2] Southeast Univ, Dept TB, Affiliated Hosp 2, Hosp Nanjing 2, Nanjing 210009, Peoples R China

[3] Nanjing Univ, Nanjing Jinling Hosp, Dept Neurosurg, Nanjing 210002, Peoples R China

[4] Chinese Acad Sci, Inst Basic Med & Canc IBMC, Zhejiang Canc Hosp, Univ Chinese Acad Sci,Dept Intervent Oncol,Canc H, Hangzhou 310022, Zhejiang, Peoples R China

来源：

JOURNAL OF NANOBIOTECHNOLOGY | 2022年 / 20卷 / 01期

基金：

中国博士后科学基金;

关键词：

Cancer immunotherapy; Nanovesicles; Liposomes; Cell membrane vesicles; Bacterial outer membrane vesicles; Extracellular vesicles; Hybrid nanovesicles; OUTER-MEMBRANE VESICLES; EXTRACELLULAR VESICLES; SUPPRESSOR-CELLS; DENDRITIC CELLS; TUMOR; EXOSOMES; VACCINATION; MICROENVIRONMENT; CARDIOTOXICITY; NANOPARTICLES;

D O I：

10.1186/s12951-022-01429-2

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Immunotherapy has gradually emerged as the most promising anticancer therapy. In addition to conventional anti-PD-1/PD-L1 therapy, anti-CTLA-4 therapy, CAR-T therapy, etc., immunotherapy can also be induced by stimulating the maturation of immune cells or inhibiting negative immune cells, regulating the tumor immune microenvironment and cancer vaccines. Lipid nanovesicle drug delivery system includes liposomes, cell membrane vesicles, bacterial outer membrane vesicles, extracellular vesicles and hybrid vesicles. Lipid nanovesicles can be used as functional vesicles for cancer immunotherapy, and can also be used as drug carriers to deliver immunotherapy drugs to the tumor site for cancer immunotherapy. Here, we review recent advances in five kinds of lipid nanovesicles in cancer immunotherapy and assess the clinical application prospects of various lipid nanovesicles, hoping to provide valuable information for clinical translation in the future.

引用

页数：22

共 133 条

[1] Doxorubicin Eliminates Myeloid-Derived Suppressor Cells and Enhances the Efficacy of Adoptive T-Cell Transfer in Breast Cancer [J].

Alizadeh, Darya ;

Trad, Malika ;

Hanke, Neale T. ;

Larmonier, Claire B. ;

Janikashvili, Nona ;

Bonnotte, Bernard ;

Katsanis, Emmanuel ;

Larmonier, Nicolas .

CANCER RESEARCH, 2014, 74 (01) :104-118

[2] Macrophage-Based Approaches for Cancer Immunotherapy [J].

Anderson, Nicholas R. ;

Minutolo, Nicholas G. ;

Gill, Saar ;

Klichinsky, Michael .

CANCER RESEARCH, 2021, 81 (05) :1201-1208

[3]

[Anonymous], 2012, ONCOLOGY-NY, V26, P841

[4] Cardioprotective effects of melatonin and metformin against doxorubicin-induced cardiotoxicity in rats are through preserving mitochondrial function and dynamics [J].

Arinno, Apiwan ;

Maneechote, Chayodom ;

Khuanjing, Thawatchai ;

Ongnok, Benjamin ;

Prathumsap, Nanthip ;

Chunchai, Titikorn ;

Arunsak, Busarin ;

Kerdphoo, Sasiwan ;

Shinlapawittayatorn, Krekwit ;

Chattipakorn, Siriporn C. ;

Chattipakorn, Nipon .

BIOCHEMICAL PHARMACOLOGY, 2021, 192

[5] Review of 10 years of research on breast cancer patients: Focus on indoleamine 2,3-dioxygenase [J].

Asghar, Kashif ;

Farooq, Asim ;

Zulfiqar, Bilal ;

Loya, Asif .

WORLD JOURNAL OF CLINICAL ONCOLOGY, 2021, 12 (06) :429-436

[6] A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy [J].

Awuah, Samuel G. ;

Zheng, Yao-Rong ;

Bruno, Peter M. ;

Hemann, Michael T. ;

Lippard, Stephen J. .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2015, 137 (47) :14854-14857

[7] DIFFUSION OF UNIVALENT IONS ACROSS LAMELLAE OF SWOLLEN PHOSPHOLIPIDS [J].

BANGHAM, AD ;

STANDISH, MM ;

WATKINS, JC .

JOURNAL OF MOLECULAR BIOLOGY, 1965, 13 (01) :238-+

[8] Doxil® - The first FDA-approved nano-drug: Lessons learned [J].

Barenholz, Yechezkel .

JOURNAL OF CONTROLLED RELEASE, 2012, 160 (02) :117-134

[9] Next-generation cell therapies: the emerging role of CAR-NK cells [J].

Basar, Rafet ;

Daher, May ;

Rezvani, Katayoun .

BLOOD ADVANCES, 2020, 4 (22) :5868-5876

[10] Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date [J].

Bobo, Daniel ;

Robinson, Kye J. ;

Islam, Jiaul ;

Thurecht, Kristofer J. ;

Corrie, Simon R. .

PHARMACEUTICAL RESEARCH, 2016, 33 (10) :2373-2387

← 1 2 3 4 5 6 7 8 9 10 →